Total Payments
$59,106
2024 Payments
$132.71
Companies
6
Transactions
47
Medicare Patients
375
Medicare Billing
$88,876
Payment Breakdown by Category
Other$27,795 (47.0%)
Consulting$21,226 (35.9%)
Travel$8,525 (14.4%)
Research$1,170 (2.0%)
Food & Beverage$389.68 (0.7%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $27,795 | 11 | 47.0% |
| Consulting Fee | $21,226 | 7 | 35.9% |
| Travel and Lodging | $8,525 | 23 | 14.4% |
| Unspecified | $1,170 | 1 | 2.0% |
| Food and Beverage | $389.68 | 5 | 0.7% |
Payments by Type
General
$57,936
46 transactions
Research
$1,170
1 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Eisai Inc. | $34,100 | 27 | $0 (2021) |
| Exelixis Inc. | $17,389 | 12 | $0 (2023) |
| Novartis Pharmaceuticals Corporation | $6,185 | 5 | $0 (2017) |
| F. Hoffmann-La Roche AG | $1,170 | 1 | $0 (2023) |
| Alexion Pharmaceuticals, Inc. | $132.71 | 1 | $0 (2024) |
| PFIZER INC. | $130.00 | 1 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $132.71 | 1 | Alexion Pharmaceuticals, Inc. ($132.71) |
| 2023 | $16,892 | 11 | Exelixis Inc. ($15,722) |
| 2022 | $16.91 | 1 | Exelixis Inc. ($16.91) |
| 2021 | $9,680 | 6 | Eisai Inc. ($8,030) |
| 2020 | $11,052 | 11 | Eisai Inc. ($11,052) |
| 2019 | $3,477 | 4 | EISAI INC. ($3,477) |
| 2018 | $4,125 | 1 | Eisai Inc. ($4,125) |
| 2017 | $13,730 | 12 | Eisai Inc. ($7,415) |
All Payment Transactions
47 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/14/2024 | Alexion Pharmaceuticals, Inc. | ULTOMIRIS (Biological) | Food and Beverage | In-kind items and services | $132.71 | General |
| Category: Rare Disease | ||||||
| 04/18/2023 | Exelixis Inc. | CABOMETYX (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,620.00 | General |
| Category: Oncology | ||||||
| 04/01/2023 | Exelixis Inc. | CABOMETYX (Drug) | Travel and Lodging | Cash or cash equivalent | $39.00 | General |
| Category: Oncology | ||||||
| 03/31/2023 | F. Hoffmann-La Roche AG | Tecentriq (Biological) | — | In-kind items and services | $1,170.00 | Research |
| Study: Safety and Efficacy of Cobimetinib Plus Atezolizumab in Patients With Solid Tumors: A Phase II, Open-Label, Multicenter, Multicohort Study • Category: BioOncology | ||||||
| 02/24/2023 | Exelixis Inc. | CABOMETYX (Drug) | Travel and Lodging | In-kind items and services | $1,938.16 | General |
| Category: Oncology | ||||||
| 02/24/2023 | Exelixis Inc. | CABOMETYX (Drug) | Travel and Lodging | In-kind items and services | $408.63 | General |
| Category: Oncology | ||||||
| 02/24/2023 | Exelixis Inc. | CABOMETYX (Drug) | Travel and Lodging | In-kind items and services | $224.00 | General |
| Category: Oncology | ||||||
| 02/24/2023 | Exelixis Inc. | CABOMETYX (Drug) | Travel and Lodging | In-kind items and services | $224.00 | General |
| Category: Oncology | ||||||
| 02/24/2023 | Exelixis Inc. | CABOMETYX (Drug) | Travel and Lodging | In-kind items and services | $218.00 | General |
| Category: Oncology | ||||||
| 02/24/2023 | Exelixis Inc. | CABOMETYX (Drug) | Travel and Lodging | In-kind items and services | $65.00 | General |
| Category: Oncology | ||||||
| 02/24/2023 | Exelixis Inc. | CABOMETYX (Drug) | Travel and Lodging | In-kind items and services | $65.00 | General |
| Category: Oncology | ||||||
| 01/13/2023 | Exelixis Inc. | CABOMETYX (Drug) | Consulting Fee | Cash or cash equivalent | $7,920.00 | General |
| Category: Oncology | ||||||
| 11/10/2022 | Exelixis Inc. | Cabometyx (Drug) | Travel and Lodging | Cash or cash equivalent | $16.91 | General |
| Category: Oncology | ||||||
| 11/12/2021 | Exelixis Inc. | CABOMETYX (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,650.00 | General |
| Category: Oncology | ||||||
| 11/11/2021 | Eisai Inc. | Lenvima (Drug) | Consulting Fee | Cash or cash equivalent | $2,280.00 | General |
| Category: Oncology | ||||||
| 05/17/2021 | Eisai Inc. | Lenvima (Drug) | Consulting Fee | Cash or cash equivalent | $1,875.00 | General |
| Category: Oncology | ||||||
| 05/11/2021 | Eisai Inc. | Lenvima (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,562.50 | General |
| Category: Oncology | ||||||
| 04/15/2021 | Eisai Inc. | Lenvima (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $750.00 | General |
| Category: Oncology | ||||||
| 02/10/2021 | Eisai Inc. | Lenvima (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,562.50 | General |
| Category: Oncology | ||||||
| 10/26/2020 | Eisai Inc. | Lenvima (Drug) | Consulting Fee | Cash or cash equivalent | $1,562.50 | General |
| Category: Oncology | ||||||
| 10/16/2020 | Eisai Inc. | Lenvima (Drug) | Consulting Fee | Cash or cash equivalent | $1,875.00 | General |
| Category: Oncology | ||||||
| 08/29/2020 | Eisai Inc. | Lenvima (Drug) | Consulting Fee | Cash or cash equivalent | $1,093.75 | General |
| Category: Oncology | ||||||
| 01/16/2020 | Eisai Inc. | Lenvima (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,125.00 | General |
| Category: Oncology | ||||||
| 01/16/2020 | Eisai Inc. | Lenvima (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,500.00 | General |
| Category: Oncology | ||||||
| 01/16/2020 | Eisai Inc. | Lenvima (Drug) | Travel and Lodging | Cash or cash equivalent | $875.60 | General |
| Category: Oncology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| Safety and Efficacy of Cobimetinib Plus Atezolizumab in Patients With Solid Tumors: A Phase II, Open-Label, Multicenter, Multicohort Study | F. Hoffmann-La Roche AG | $1,170 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 5 | 83 | 186 | $56,702 | $19,636 |
| 2022 | 6 | 109 | 232 | $70,404 | $26,004 |
| 2021 | 4 | 109 | 279 | $79,819 | $29,753 |
| 2020 | 4 | 74 | 169 | $49,412 | $13,482 |
Total Patients
375
Total Services
866
Medicare Billing
$88,876
Procedure Codes
19
All Medicare Procedures & Services
19 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 27 | 105 | $35,881 | $13,023 | 36.3% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 13 | 13 | $6,301 | $2,102 | 33.4% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 14 | 14 | $6,804 | $2,007 | 29.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 12 | 17 | $4,375 | $1,477 | 33.8% |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Facility | 2023 | 17 | 37 | $3,341 | $1,027 | 30.7% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 36 | 134 | $45,292 | $17,382 | 38.4% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 13 | 13 | $6,253 | $2,184 | 34.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 15 | 24 | $6,024 | $2,045 | 34.0% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 12 | 12 | $5,832 | $1,967 | 33.7% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 12 | 16 | $4,000 | $1,468 | 36.7% |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Facility | 2022 | 21 | 33 | $3,003 | $958.68 | 31.9% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 36 | 150 | $50,700 | $19,738 | 38.9% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 24 | 55 | $13,805 | $4,895 | 35.5% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 22 | 22 | $10,582 | $3,581 | 33.8% |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Facility | 2021 | 27 | 52 | $4,732 | $1,539 | 32.5% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 34 | 112 | $28,184 | $7,377 | 26.2% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 15 | 32 | $10,816 | $3,085 | 28.5% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Facility | 2020 | 14 | 14 | $6,734 | $1,980 | 29.4% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2020 | 11 | 11 | $3,678 | $1,041 | 28.3% |
About Dr. Ann Gramza, M.D
Dr. Ann Gramza, M.D is a Hematology & Oncology healthcare provider based in Washington, District of Columbia. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/18/2007. The National Provider Identifier (NPI) number assigned to this provider is 1760690069.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Ann Gramza, M.D has received a total of $59,106 in payments from pharmaceutical and medical device companies, with $132.71 received in 2024. These payments were reported across 47 transactions from 6 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($27,795).
As a Medicare-enrolled provider, Gramza has provided services to 375 Medicare beneficiaries, totaling 866 services with total Medicare billing of $88,876. Data is available for 4 years (2020–2023), covering 19 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Washington, DC
- Active Since 05/18/2007
- Last Updated 06/09/2015
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1760690069
Products in Payments
- Lenvima (Drug) $34,100
- CABOMETYX (Drug) $17,372
- MEKINIST (Drug) $5,171
- Tecentriq (Biological) $1,170
- TAFINLAR (Drug) $1,014
- ULTOMIRIS (Biological) $132.71
- BAVENCIO (Drug) $130.00
- Cabometyx (Drug) $16.91
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Washington
Imad Tabbara, M.d, M.D
Hematology & Oncology — Payments: $1.8M
Hematology & Oncology $1.8M
John Marshall
Hematology & Oncology — Payments: $770,250
Hematology & Oncology $770,250
Dr. Catherine Broome, Md, MD
Hematology & Oncology — Payments: $693,161
Hematology & Oncology $693,161
Craig Kessler
Hematology & Oncology — Payments: $632,186
Hematology & Oncology $632,186
Claudine Isaacs
Hematology & Oncology — Payments: $406,847
Hematology & Oncology $406,847
Muhammad Mirza, M.d, M.D
Hematology & Oncology — Payments: $118,419
Hematology & Oncology $118,419